Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel

Chudy, M.; Scheiblauer, Heinrich; Hanschmann, K.-M.; Kreß, Julia; Nick, Sigrid; Wend, Ulrike C.; Schüttler, Christian G.; Nübling, C. Micha; Gerlich, Wolfram H.

doi:10.1016/j.jcv.2013.06.011

Cited by 30 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As this assay gives very reproducible signals over a wide range of concentrations (Gerlich, unpublished results), independently of the HBV genotype,26 HBsAg concentrations (total HBsAg) were obtained by calibration with the PEI-Standard (Paul-Ehrlich-Institut, Langen, Germany). In the confirmatory cohort, HBsAg levels were measured in parallel by the HBsAg Architect immune assay (Abbott Diagnostics, Germany).…”

Section: Methodsmentioning

confidence: 99%

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Pfefferkorn

Böhm

Schott

et al. 2017

Gut

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Pfefferkorn

Böhm

Schott

et al. 2017

Gut

View full text Add to dashboard Cite

show abstract

“…The Elecsys Assay has an automatic on board dilution with a range of quantification from 0.05 to 52 000 IU/ml. The assays express results in international units per millilitre (IU/ml), based on the WHO reference standard, with 1 IU/ml equivalent to 1–10 ng/ml of HBsAg or 5x10 7 virions . Results with both assays are highly correlated and in close agreement for all HBV genotypes.…”

Section: Optimizing Treatment Monitoring Using Hbsag Quantification: mentioning

confidence: 99%

HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

Martinot–Peignoux

Asselah

Marcellin

2014

Liver International

View full text Add to dashboard Cite

Hepatitis B surface antigen (HBsAg) levels in serum have been shown to reflect active intrahepatic covalently closed circular DNA (cccDNA) and to have additional value as a marker of on-treatment efficacy. In the past few years, immunoassays to quantify HBsAg have been developed to monitor HBsAg kinetics during treatment. Although HBsAg quantification cannot replace HBV DNA measurement in clinical practice, the combined use of HBsAg quantification and HBV DNA measurements could help predict treatment outcome. One of the most important results of the studies in this new marker is that a decline in HBsAg titres during pegylated-interferon (PEG-IFN) treatment is a strong predictor of response so that a 'week 12 stopping rule' could be established for both Hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients. However, the positive predictive value (PPV) for a sustained viral response (SVR) remains low. The role of HBsAg measurements during nucloes(t)ides analogue (NAs) treatment is unclear. It may be a useful marker for stopping NAs by limiting the chance of relapse or for add-on strategies. Monitoring serum HBsAg levels in chronic hepatitis B (CHB) patients during treatment may provide significant complementary information to HBV DNA measurements. Key Points• Serum hepatitis B surface antigen (HBsAg) level reflects the transcriptional activity of covalently closed circular DNA in the liver.

show abstract

“…Preliminary data suggest good overall statistical correlations; however, since some assays have shown genotype-dependent differences in analytical sensitivity, clinical decision-making in the single patient should rely only on monitoring performed with the same assay [43]. …”

Section: Towards Treatment Personalizationmentioning

confidence: 99%

Interferon Therapy of Chronic Hepatitis B

Brunetto¹,

Bonino

2014

Intervirology

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) results from the inability of the host's immune system to control viral replication. Interferon-α (IFN-α) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients. In spite of the low response rate, IFN-α therapy has the advantage of having a limited duration and being effective even after therapy, as demonstrated by a much higher incidence of HBsAg clearance in responders to IFN-α than in naturally occurring inactive HBsAg carriers. IFN-α has multiple antiviral, antiproliferative, and immunomodulatory activities and targets: cellular genes (IFN-stimulated genes) activating different pathways of antiviral defense in infected and noninfected cells, HBV replication blocking the RNA-containing core particle formation and accelerating their decay, degrading pregenomic RNA, and modulating the nuclear viral minichromosome (covalently closed circular DNA) activity by targeting its epigenetic regulation and both innate and adaptive immune response. The interference of viral heterogeneity and genetic polymorphisms of the host on IFN-α susceptibility is under investigation. Only a better understanding of the complex interplay between the different activities of IFN-α would warrant the amelioration of current therapeutic strategies and the design of new therapeutic approaches. The study of on-treatment dynamics of HBV infection by means of combined quantitative monitoring of serum HBV DNA and HBsAg warrant tailoring treatment at the single-patient level and can help to make treatment more cost-effective by using the different combinations of currently available antivirals, including IFN, more appropriately. Integrated molecular and clinical knowledge in a systems medicine fashion is mandatory to further improve antiviral therapy in CHB.

show abstract

Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel

Cited by 30 publications

References 19 publications

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

Interferon Therapy of Chronic Hepatitis B

Contact Info

Product

Resources

About